Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Eur J Haematol. 2017 Mar 28;98(6):529–541. doi: 10.1111/ejh.12870

Figure 4. Schematic of active (targeted) nanoparticles in cancer.

Figure 4

Nanoparticles extravasate from the vasculature due to EPR effect, then targeted nanoparticles bind and internalize into tumor tissues, the retention and uptake of these nanoparticles in cancer cells (brown) is augmented due to specific antigen-antibody/ ligand-receptor interactions, and wash out of nanoparticles is reduced.